Physician profile
Paul Ndunda
NPI 1871848713
$1,390.82
in general payments reported to CMS, 2019-2025
14 companies · $499 in 2025
The $499 reported for 2025 was more than what 90% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $105 · 2023: $275 · 2024: $337 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $415.80 | 2023-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $211.66 | 2022-2025 | Lifevest |
| Abbott Laboratories | $146.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $133.21 | 2024-2025 | |
| Pfizer INC. | $100.88 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $89.53 | 2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $80.08 | 2023-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $43.91 | 2022 | |
| Bridgebio Pharma, INC. | $36.27 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $35.83 | 2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.68 | 2021-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $26.02 | 2023 | Opsumit, Uptravi |
| Novo Nordisk INC | $18.76 | 2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $18.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Ndunda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.